ATA17892000A - Vakzin-zusammensetzung - Google Patents

Vakzin-zusammensetzung

Info

Publication number
ATA17892000A
ATA17892000A AT0178900A AT17892000A ATA17892000A AT A17892000 A ATA17892000 A AT A17892000A AT 0178900 A AT0178900 A AT 0178900A AT 17892000 A AT17892000 A AT 17892000A AT A17892000 A ATA17892000 A AT A17892000A
Authority
AT
Austria
Prior art keywords
peptide
amino acid
acid residue
group
antigen
Prior art date
Application number
AT0178900A
Other languages
English (en)
Other versions
AT410635B (de
Original Assignee
Cistem Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0178900A priority Critical patent/AT410635B/de
Application filed by Cistem Biotechnologies Gmbh filed Critical Cistem Biotechnologies Gmbh
Priority to PL362966A priority patent/PL209016B1/pl
Priority to IL15460501A priority patent/IL154605A0/xx
Priority to PT01980496T priority patent/PT1326634E/pt
Priority to CZ20031299A priority patent/CZ303303B6/cs
Priority to AT01980496T priority patent/ATE324116T1/de
Priority to DE60119145T priority patent/DE60119145T2/de
Priority to HU0302117A priority patent/HU228382B1/hu
Priority to CA2426490A priority patent/CA2426490C/en
Priority to KR1020037004977A priority patent/KR100598302B1/ko
Priority to CNB018171168A priority patent/CN1248736C/zh
Priority to SI200130564T priority patent/SI1326634T1/sl
Priority to NZ524532A priority patent/NZ524532A/en
Priority to AU1232602A priority patent/AU1232602A/xx
Priority to RU2003114434/15A priority patent/RU2328305C2/ru
Priority to ES01980496T priority patent/ES2263668T3/es
Priority to PCT/EP2001/012041 priority patent/WO2002032451A1/en
Priority to SK575-2003A priority patent/SK287618B6/sk
Priority to DK01980496T priority patent/DK1326634T3/da
Priority to US10/399,442 priority patent/US8361476B2/en
Priority to BRPI0114994-6 priority patent/BRPI0114994B8/pt
Priority to MXPA03002828A priority patent/MXPA03002828A/es
Priority to AU2002212326A priority patent/AU2002212326B2/en
Priority to JP2002535688A priority patent/JP4227407B2/ja
Priority to EP01980496A priority patent/EP1326634B1/de
Publication of ATA17892000A publication Critical patent/ATA17892000A/de
Priority to IS6722A priority patent/IS2608B/is
Priority to ZA200301465A priority patent/ZA200301465B/en
Priority to IL154605A priority patent/IL154605A/en
Priority to NO20031595A priority patent/NO330274B1/no
Application granted granted Critical
Publication of AT410635B publication Critical patent/AT410635B/de
Priority to HK03108189A priority patent/HK1055899A1/xx
Priority to RU2007146372/15A priority patent/RU2007146372A/ru
Priority to US12/124,785 priority patent/US8900564B2/en
Priority to JP2008134215A priority patent/JP2008222721A/ja
Priority to US13/742,500 priority patent/US20130216583A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT0178900A 2000-10-18 2000-10-18 Vakzin-zusammensetzung AT410635B (de)

Priority Applications (34)

Application Number Priority Date Filing Date Title
AT0178900A AT410635B (de) 2000-10-18 2000-10-18 Vakzin-zusammensetzung
US10/399,442 US8361476B2 (en) 2000-10-18 2001-10-18 Vaccine composition comprising an antigen and a peptide having adjuvant properties
SK575-2003A SK287618B6 (sk) 2000-10-18 2001-10-18 Vakcína obsahujúca aspoň jeden antigén a peptid a použitie tohto peptidu
IL15460501A IL154605A0 (en) 2000-10-18 2001-10-18 Vaccine composition
AT01980496T ATE324116T1 (de) 2000-10-18 2001-10-18 Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung
DE60119145T DE60119145T2 (de) 2000-10-18 2001-10-18 Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung
HU0302117A HU228382B1 (en) 2000-10-18 2001-10-18 Vaccine composition
CA2426490A CA2426490C (en) 2000-10-18 2001-10-18 Vaccine composition comprising an antigen and a peptide having adjuvant properties
KR1020037004977A KR100598302B1 (ko) 2000-10-18 2001-10-18 백신 조성물
CNB018171168A CN1248736C (zh) 2000-10-18 2001-10-18 疫苗组合物
SI200130564T SI1326634T1 (sl) 2000-10-18 2001-10-18 Vakcinski sestavek, ki obsega antigen in peptid zadjuvantnimi lastnostmi
NZ524532A NZ524532A (en) 2000-10-18 2001-10-18 Vaccine composition
AU1232602A AU1232602A (en) 2000-10-18 2001-10-18 Vaccine composition
RU2003114434/15A RU2328305C2 (ru) 2000-10-18 2001-10-18 Вакцинная композиция
ES01980496T ES2263668T3 (es) 2000-10-18 2001-10-18 Composicion de vacuna que comprende un antigeno y un peptido con propiedades adyuvantes.
PCT/EP2001/012041 WO2002032451A1 (en) 2000-10-18 2001-10-18 Vaccine composition comprising an antigen and a peptide having adjuvant properties
PL362966A PL209016B1 (pl) 2000-10-18 2001-10-18 Kompozycja szczepionek i zastosowanie polipeptydu do wytwarzania adiuwantu lub białka nośnikowego
CZ20031299A CZ303303B6 (cs) 2000-10-18 2001-10-18 Složená vakcína
DK01980496T DK1326634T3 (da) 2000-10-18 2001-10-18 Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber
BRPI0114994-6 BRPI0114994B8 (pt) 2000-10-18 2001-10-18 composição de vacina
MXPA03002828A MXPA03002828A (es) 2000-10-18 2001-10-18 Composicion de vacuna.
AU2002212326A AU2002212326B2 (en) 2000-10-18 2001-10-18 Vaccine composition comprising an antigen and a peptide having adjuvant properties
JP2002535688A JP4227407B2 (ja) 2000-10-18 2001-10-18 ワクチン組成物
EP01980496A EP1326634B1 (de) 2000-10-18 2001-10-18 Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung
PT01980496T PT1326634E (pt) 2000-10-18 2001-10-18 Composicao de vacina compreendendo um antigenio e um peptido possuindo propriedades adjuvantes
IS6722A IS2608B (is) 2000-10-18 2003-02-20 Bóluefnissamsetning sem samanstendur af mótefnisvaka og peptíði sem hefur ónæmisglæðandi eiginleika.
ZA200301465A ZA200301465B (en) 2000-10-18 2003-02-24 Vaccine composition comprising an antigen and a peptide having adjuvant properties.
IL154605A IL154605A (en) 2000-10-18 2003-02-24 A preparation that includes a peptide that is able to increase the immune response to the antigen given - jointly
NO20031595A NO330274B1 (no) 2000-10-18 2003-04-08 Vaksine som omfatter minst ett antigen og et peptid med gitt sekvens, og anvendelse av peptidet til fremstilling av en adjuvans eller et baereprotein
HK03108189A HK1055899A1 (en) 2000-10-18 2003-11-12 Vaccine composition comprising an antigen and a peptide having adjuvant properties
RU2007146372/15A RU2007146372A (ru) 2000-10-18 2007-12-13 Вакцинная композиция
US12/124,785 US8900564B2 (en) 2000-10-18 2008-05-21 Vaccine composition comprising an antigen and a peptide having adjuvant properties
JP2008134215A JP2008222721A (ja) 2000-10-18 2008-05-22 ワクチン組成物
US13/742,500 US20130216583A1 (en) 2000-10-18 2013-01-16 Vaccine composition comprising an antigen and a peptide having adjuvant properties

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0178900A AT410635B (de) 2000-10-18 2000-10-18 Vakzin-zusammensetzung

Publications (2)

Publication Number Publication Date
ATA17892000A true ATA17892000A (de) 2002-11-15
AT410635B AT410635B (de) 2003-06-25

Family

ID=3688953

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0178900A AT410635B (de) 2000-10-18 2000-10-18 Vakzin-zusammensetzung
AT01980496T ATE324116T1 (de) 2000-10-18 2001-10-18 Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01980496T ATE324116T1 (de) 2000-10-18 2001-10-18 Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung

Country Status (27)

Country Link
US (3) US8361476B2 (de)
EP (1) EP1326634B1 (de)
JP (2) JP4227407B2 (de)
KR (1) KR100598302B1 (de)
CN (1) CN1248736C (de)
AT (2) AT410635B (de)
AU (2) AU2002212326B2 (de)
BR (1) BRPI0114994B8 (de)
CA (1) CA2426490C (de)
CZ (1) CZ303303B6 (de)
DE (1) DE60119145T2 (de)
DK (1) DK1326634T3 (de)
ES (1) ES2263668T3 (de)
HK (1) HK1055899A1 (de)
HU (1) HU228382B1 (de)
IL (2) IL154605A0 (de)
IS (1) IS2608B (de)
MX (1) MXPA03002828A (de)
NO (1) NO330274B1 (de)
NZ (1) NZ524532A (de)
PL (1) PL209016B1 (de)
PT (1) PT1326634E (de)
RU (2) RU2328305C2 (de)
SI (1) SI1326634T1 (de)
SK (1) SK287618B6 (de)
WO (1) WO2002032451A1 (de)
ZA (1) ZA200301465B (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
JP2004519452A (ja) * 2001-01-05 2004-07-02 インターツェル・アクチェンゲゼルシャフト ポリカチオン性化合物の用途
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1279404A1 (de) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Verwendung von HIV-1 Fragmenten oder Derivaten zur Bestimmung oder Aktivierung von Antigen-präsentierenden Zellen, oder zur Abgabe von Cargo-Molekülen für Impfung oder für Behandlung von anderen Erkrankungen
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
JP2006504687A (ja) 2002-09-13 2006-02-09 インターツェル・アクチェンゲゼルシャフト Ｃ型肝炎ウイルスペプチドの単離方法
WO2004035618A2 (en) 2002-10-15 2004-04-29 Intercell Ag Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
DE602004022923D1 (de) 2003-03-04 2009-10-15 Intercell Ag Streptococcus pyogenes antigene
WO2004084937A1 (en) * 2003-03-24 2004-10-07 Intercell Ag Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses
ES2562456T3 (es) * 2003-03-24 2016-03-04 Valneva Austria Gmbh Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
JP2007523609A (ja) 2003-03-31 2007-08-23 インターツェル・アクチェンゲゼルシャフト 表皮ブドウ球菌抗原
CA2522238A1 (en) 2003-04-15 2004-10-28 Intercell Ag S. pneumoniae antigens
US8076059B2 (en) 2003-04-16 2011-12-13 Duke University Adjuvant capable of specifically activating the adaptive immune response
JP2007535894A (ja) 2003-05-07 2007-12-13 インターツェル・アクチェンゲゼルシャフト ストレプトコッカス・アガラクティエ抗原ｉ＋ｉｉ
EP2327720A1 (de) 2003-05-30 2011-06-01 Intercell AG Enterokokken-Antigene
CN1822856B (zh) * 2003-07-11 2010-04-28 英特塞尔股份公司 Hcv疫苗
ES2297688T3 (es) 2004-03-12 2008-05-01 Intercell Ag Procedimiento para solubizar mezclas de peptidos.
ES2344739T3 (es) 2004-09-24 2010-09-06 Intercell Ag Proteina capsidial vp1 modificada del parvovirus b19.
EP2471550A1 (de) 2005-10-07 2012-07-04 Health Protection Agency Proteine mit verbesserter Löslichkeit und Verfahren zu ihrer Herstellung und Verwendung
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2008000261A2 (en) 2006-06-28 2008-01-03 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
JP2009542196A (ja) 2006-07-07 2009-12-03 インターセル アーゲー 小型の化膿連鎖球菌抗原およびそれらの使用
AU2007295927A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2675379A1 (en) 2007-01-12 2008-07-17 Intercell Ag Protective proteins of s. agalactiae, combinations thereof and methods of using the same
US8236326B2 (en) 2007-05-02 2012-08-07 Intercell Ag Klebsiella antigens
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
EP2012122A1 (de) 2007-07-06 2009-01-07 Medigene AG Strukturproteine von mutierten Parvoviren als Impfstoffe
EP2167530A2 (de) 2007-06-18 2010-03-31 Intercell AG Chlamydia-antigene
CA2718473A1 (en) 2008-03-17 2009-09-24 Intercell Ag Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
EP2281574B1 (de) 2008-04-02 2014-07-09 The University of Tokushima Antigen-und-arznei-vehikel mit einem synthetischen peptid und dieses verwendender mukosaler impfstoff
KR20110031343A (ko) 2008-06-20 2011-03-25 와이어쓰 엘엘씨 베타-용혈성 스트렙토코커스 균주로부터 유래된 ｏｒｆ1358을 사용하는 조성물 및 방법
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
US20130243779A1 (en) 2009-02-05 2013-09-19 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
US8617574B2 (en) 2009-02-13 2013-12-31 Valneva Austria Gmbh Nontypable Haemophilus influenzae antigens
PE20110023A1 (es) 2009-06-22 2011-01-31 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus
EP3461496B1 (de) 2009-06-22 2023-08-23 Wyeth LLC Zusammensetzungen und verfahren zur herstellung von staphylococcus aureus serotyp-5 und 8-kapselpolysaccharid-konjugat-immunogenzusammensetzungen
NZ598459A (en) 2009-08-27 2014-03-28 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
EP2319871A1 (de) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
PE20121689A1 (es) 2009-10-09 2012-12-14 Sanofi Sa Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos
EP2308896A1 (de) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
JP2013522287A (ja) 2010-03-18 2013-06-13 ノバルティス アーゲー 血清群ｂ髄膜炎菌のためのアジュバント添加ワクチン
KR101609032B1 (ko) 2010-06-04 2016-04-04 와이어쓰 엘엘씨 스트렙토코커스 뉴모니아 백신 제제
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
BR112014004896B1 (pt) 2010-09-03 2023-02-14 Valneva Usa, Inc. Polipepttdeo isolado de proteínas de toxina a e toxina b de c. difficile e usos do mesmo
WO2012031760A1 (en) 2010-09-08 2012-03-15 Medigene Ag Parvovirus mutated structural proteins comprising cross - protective b - cell epitopes of a hpv l2 protein as well as products and methods relating thereto
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
KR20130114210A (ko) 2010-12-22 2013-10-16 와이어쓰 엘엘씨 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
EP2847322B1 (de) 2012-05-08 2019-06-26 Western University Of Health Sciences Standardisierte ex-vivo-plattformen zur antigenspezifischen expansion der cd4+-t-zell-populationen
WO2014070709A1 (en) * 2012-10-29 2014-05-08 The Board Of Trustees Of The University Of Arkansas Novel mucosal adjuvants and delivery systems
PL3363806T3 (pl) 2012-12-20 2022-12-19 Pfizer Inc. Sposób glikokoniugacji
EP2964665B1 (de) 2013-03-08 2018-08-01 Pfizer Inc Immunogene fusionspolypeptide
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
TWI718144B (zh) 2015-05-04 2021-02-11 美商輝瑞股份有限公司 Ｂ型鏈球菌多醣－蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
CN107441501B (zh) * 2016-07-01 2020-11-10 四川大学 抗菌肽修饰的载药脂质体及其制备方法和用途
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
CN107266585B (zh) * 2017-07-13 2019-08-06 陕西科技大学 一种mlh融合抗菌肽及其制备方法和应用
EP3527223A1 (de) 2018-02-16 2019-08-21 2A Pharma AB Mutiertes parvovirus-strukturprotein
JP2021513840A (ja) 2018-02-16 2021-06-03 ２エー ファーマ アーベー 自己免疫疾患の処置のためのパルボウイルス構造タンパク質
CN109745556A (zh) * 2019-03-01 2019-05-14 龙阔（苏州）生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
AU2020277661A1 (en) 2019-05-20 2021-10-21 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection
US20230137756A1 (en) * 2020-03-30 2023-05-04 The Wistar Institute Of Anatomy And Biology Synthetic Soluble Receptor Mimics and Methods of Use for Treatment of COVID-19
WO2021211279A1 (en) 2020-04-17 2021-10-21 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
EP4203995A1 (de) 2020-08-26 2023-07-05 Pfizer Inc. Gruppe-b-streptococcus-polysaccharid-protein-konjugate, verfahren zur herstellung von konjugaten, immunogene zusammensetzungen mit konjugaten und verwendungen davon
JP2024522385A (ja) 2021-04-09 2024-06-19 ヴァルネヴァ エスイー ヒトメタニューモウイルスワクチン
WO2023083964A1 (en) 2021-11-11 2023-05-19 2A Pharma Ab Parvovirus structural protein against beta- and gamma-hpv
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09502086A (ja) * 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
JP3442824B2 (ja) * 1993-08-30 2003-09-02 理化学研究所 抗菌性ペプチド類
JP3547504B2 (ja) * 1994-11-01 2004-07-28 独立行政法人理化学研究所 新規なポリペプチド及びその用途
US6261568B1 (en) * 1997-06-11 2001-07-17 Institut Pasteur Attenuated recombinant mycobacteria useful as immunogens or as vaccine components
EP1009386B1 (de) * 1997-08-29 2005-08-31 Corixa Corporation Schnellfreisetzende enkapsulierte bioaktive wirkstoffe zur induzierung einer immunantwort und verwendung derselben
CU22700A1 (es) * 1997-09-29 2001-07-31 Ct Ingenieria Genetica Biotech Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso
US20020072495A1 (en) * 2000-09-21 2002-06-13 Oleg Chertov LL-37 is an immunostimulant
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
ES2562456T3 (es) * 2003-03-24 2016-03-04 Valneva Austria Gmbh Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
WO2004084937A1 (en) * 2003-03-24 2004-10-07 Intercell Ag Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses
CN1822856B (zh) * 2003-07-11 2010-04-28 英特塞尔股份公司 Hcv疫苗

Also Published As

Publication number Publication date
DE60119145D1 (de) 2006-06-01
KR100598302B1 (ko) 2006-07-07
WO2002032451A1 (en) 2002-04-25
PT1326634E (pt) 2006-09-29
JP2004511528A (ja) 2004-04-15
AU1232602A (en) 2002-04-29
BRPI0114994B8 (pt) 2021-05-25
HU228382B1 (en) 2013-03-28
HUP0302117A3 (en) 2004-11-29
ATE324116T1 (de) 2006-05-15
CA2426490C (en) 2012-01-31
NO20031595D0 (no) 2003-04-08
DK1326634T3 (da) 2006-08-14
RU2328305C2 (ru) 2008-07-10
BR0114994A (pt) 2003-09-30
WO2002032451A8 (en) 2002-05-23
US20130216583A1 (en) 2013-08-22
SK5752003A3 (en) 2003-12-02
US8900564B2 (en) 2014-12-02
KR20030043993A (ko) 2003-06-02
HUP0302117A2 (hu) 2003-09-29
NZ524532A (en) 2004-10-29
HK1055899A1 (en) 2004-01-30
CN1468109A (zh) 2004-01-14
NO330274B1 (no) 2011-03-14
SI1326634T1 (sl) 2006-10-31
IL154605A0 (en) 2003-09-17
IL154605A (en) 2009-05-04
US20050063978A1 (en) 2005-03-24
IS6722A (is) 2003-02-20
AU2002212326B2 (en) 2006-01-05
US20090123486A1 (en) 2009-05-14
ES2263668T3 (es) 2006-12-16
IS2608B (is) 2010-04-15
CA2426490A1 (en) 2002-04-25
PL362966A1 (en) 2004-11-02
SK287618B6 (sk) 2011-04-05
CZ20031299A3 (cs) 2003-10-15
MXPA03002828A (es) 2003-07-14
US8361476B2 (en) 2013-01-29
DE60119145T2 (de) 2007-02-01
EP1326634B1 (de) 2006-04-26
BRPI0114994B1 (pt) 2017-11-07
EP1326634A1 (de) 2003-07-16
JP4227407B2 (ja) 2009-02-18
RU2007146372A (ru) 2009-06-20
CZ303303B6 (cs) 2012-07-25
NO20031595L (no) 2003-06-05
JP2008222721A (ja) 2008-09-25
ZA200301465B (en) 2004-02-24
CN1248736C (zh) 2006-04-05
AT410635B (de) 2003-06-25
PL209016B1 (pl) 2011-07-29

Similar Documents

Publication Publication Date Title
ATA17892000A (de) Vakzin-zusammensetzung
PL324531A1 (en) Derivatives of cyclosporin effective against hiv virus
ATE557041T1 (de) Peptid-vakzinen gegen streptokokken der gruppe a
DE60329201D1 (de) Substituierte wt1-peptide
ATE429448T1 (de) Peptidzusammensetzung als immunogen zur allergiebehandlung.
PT1290013E (pt) Derivados dos peptidos apo-ai/aii
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
ATE300619T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
BR0309491A (pt) Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
EP1796707A4 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
WO2003097678A3 (en) Use of the repressor glxr for the synthesis of lysine in corynebacterium glutamicum
EA200100314A1 (ru) Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
MXPA02012664A (es) Peptidos para la preparacion de vacunas contra bordetella pertussis y bordetella parapertussis.
WO1994004565A3 (en) Ipnv vaccine
NZ508812A (en) Peptides for the prevention or treatment of HIV
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
DE60124299D1 (de) Peptide aus dem b-glycoprotein des menschlichen herpesvirus-7, besonders anwendbar bei serologischen elisa-nachweisen
EP0290246A3 (de) Impfstoff zur Erzeugung einer gegen Tollwutvirus schützenden immunogenen T-Zellen-Respons

Legal Events

Date Code Title Description
PC Change of the owner

Owner name: INTERCELL AG, AT

Effective date: 20120919

PC Change of the owner

Owner name: VALNEVA AUSTRIA GMBH, AT

Effective date: 20140611

MK07 Expiry

Effective date: 20201018